

Prostatype Genomics U.S. Validation study by Veterans Affairs (VA) is published

Prostatype Genomics is pleased to announce that the study performed in USA under the leadership of professor Stephen Freedland at Department of Urology at Cedars-Sinai, and in association with the Durham Veteran Affairs Healthcare System, has been accepted and is published in the medical journal Prostate Cancer and Prostatic Diseases. Veterans Affairs is one of the world's largest integrated health care systems where Cedars-Sinai is ranked among the top 10 most influential hospitals in USA.

The study includes a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test across a broad demographic setting.

CEO of Prostatype Genomics, Fredrik Rickman, comments: "We are obviously happy that the study results are positive and well in line with what we have seen in other published studies with Prostatype®, emphasizing the performance of the product. It has been a pleasure for Prostatype Genomics to collaborate with such distinguished and professional organizations as the Veterans Affairs, Cedars-Sinai Health System and more specifically professor Freedland and his team."

In summary the study results shows that Prostatype® has a strong and significant predictive ability to identify the men that really has a high risk of dying from prostate cancer which is the type of clinical information that doctors and health care payers are looking for. Furthermore, also seen in other published studies, Prostatype® significantly outperforms existing clinical prognostic tools adding additional clinical benefit for patients, doctors and health care providers. Notably, no significant difference was observed in the test's performance between African American and Caucasian patients, reinforcing Prostatype's robustness and reliability across different patient groups.

"Decision Curve Analysis shows that Prostatype® supports doctors and patients to make better and more accurate treatment decisions – both when it comes to avoid unnecessary and costly overtreatment and at the same time clearly identify patients who really needs early intervention. It is a well-known fact that overtreatment of prostate cancer patients around the world is common and many times leads to unnecessary side effects, reduced quality of life for many patients and unnecessary costs for health care providers, so once more Prostatype® has proven its clinical and financial value" says Fredrik Rickman.

"The purpose of the study was that the Company in early stages of our journey understood the importance of actually being able to show strong data generated in the United States, from a commercial as well as from a reimbursement point of view. We are in the final stages in the process of receiving coverage by Medicare why the official publication of this study comes at an excellent point in time" concludes Fredrik Rickman.

The full scientific journal with the results from the health economics study can be read here:

<https://www.nature.com/articles/s41391-025-01070-8>

For more information, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

Email: fredrik.rickman@prostatypegenomics.com

Certified Adviser

Tapper Partners AB

Telephone: +46 (0)70 44 010 98

E-mail: ca@tapperpartners.se

About Prostatype Genomics AB

Prostatype® is a genetic test available to patients and treating urologists as a complementary decision-making tool when considering treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.